A new study reveals how gut bacteria may initiate ulcerative colitis by weakening immune defenses before inflammation occurs.

The company cut 40% of its workforce earlier this year and now is seeking a partner for a late-stage clinical trial. The signature drug from a Peninsula biotech company was bested in a mid-stage ...

Diseases and disorders particularly that of bowels and digestive process is more common than others and colitis is one such common disease that is experienced by countless people all over the world.

Johnson & Johnson (NYSE:JNJ) said on Monday that its mid-stage study of icotrokinra, for the treatment of moderate to severe active ulcerative colitis, met the main goal. JNJ stock up about 1% in ...

Upadacitinib (RINVOQ™), an oral, once-daily, selective, and reversible JAK inhibitor developed by AbbVie Inc. (NYSE:ABBV) has met all primary and ranked secondary endpoints in an ongoing Phase 2b/3 ...

Bristol-Myers Squibb’s Zeposia colitis treatment met both its primary goals in a late-stage study. Bristol-Myers Squibb (BMY) said Tuesday that Zeposia, its treatment for moderate to severe ulcerative ...

Palatin Technologies Inc. (NYSE:PTN) on Friday released topline results from its Phase 2 study of PL8177, a selective melanocortin-1 receptor (MC1R) agonist, in patients with active ulcerative colitis ...

Oct 4 (Reuters) - Salix Pharmaceuticals Ltd said a second late-stage trial of its new granulated mesalamine product to treat ulcerative colitis showed positive results. The specialty pharmaceutical ...